Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN: L85195TG1984PLC004507 | |
| Tel : +91 40 4900 2900 | |
| Fax : +91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. | |
| BSE Limited | "Exchange Plaza" | |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |
| Mumbai - 400 001 | Mumbai - 400 051 | |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ | |
| 22722037 / 22722039 | 26598238 | |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's to release Q3 FY19 results on February 1, 2019, Earnings call slated for February 1, 6:30 PM IST / 8:00
This is for your information.
| With regards, | |
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS | Media relationS |
| AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | Calvin Printer calvinprinter@drreddys.com (Ph: +91-40- 49002121) |
Reddy's to release Q3 FY19 results on February 1, 2019
Earnings call slated for February 1, 6:30 PM IST / 8:00 AM EST
India, January 11, 2019
Dr. Reddy's Laboratories (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended December 31, 2018 on Friday, February 1, 2019 after the Board
| Event | Date and Time | Medium |
| Release of financial results | February 1 st , after the Board Meeting | Email, Media, Company website, Business wire |
| Press meet presentation | Will be available on the Company's website | URL available on Company's website, www.drreddys.com |
| Earnings Call | February 1 st , 6:30 PM IST / 8:00 AM EST | Hosted by the Company (Details below) |
| Playback of Earnings Call | After the earnings call till February 7 th | Details below |
| Transcript of the Earnings call | Will be available on the Company's website | URL available on Company's website, www.drreddys.com |
Following the release, the management of
the Company will host an earnings call to discuss the Company's financial performance. (Dial In and other details given
The play back will be available after the
earnings call, through February 7th, 2019. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and Playback
| Conference Dial-In Numbers | |
| Universal Access Number: | +91 22 6280 1219 +91 22 7115 8120 |
| Local Access Number: Available all over India | +91 70456 71221 |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the
above numbers. The operator will provide instructions on asking questions before and during the call.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated
pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses
- Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers
a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management
and dermatology. Dr Reddy's operates in markets across the globe. Our Major markets include - USA, India, Russia &
CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release
may include statements of future expectations and other forward-looking statements that are based on the management's current
views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events
to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by
reason of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from
those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization
, including related integration issues.
no obligation to update any information contained herein.